Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-PRP-IIRA: DOD, Parkinson's Investigator-Initiated Research Award

Closed Closed August 17, 2023 Opportunity HT9425-23-PRP-IIRA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

• Total funding$6.0 million
• Expected awards4
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's research. This award mechanism supports the full spectrum of research from basic science through clinical research. The following are important aspects of the IIRA: Research Strategy and Feasibility: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of the neurodegenerative effects of PD. Experimental strategies may be novel or may be based on strong rationale derived from previously published data, presented preliminary data, or literature review. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Preliminary data to support feasibility are encouraged but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or member(s) of the research team. The preliminary data must support the feasibility of the study. Clinical trials may be supported by this award mechanism and require the submission of Attachment 8: Clinical Strategy Statement. Impact: The proposed research should impact an area of paramount importance in PD. The application must clearly and explicitly describe the potential short-term and long-term impact of the proposed study and convey its level of significance. The research should benefit individuals with PD. Focus Area: The proposed research must address at least one of the two FY23 PRP Focus Areas. Principal Investigator and Research Team: The PRP seeks applications from investigators working in a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. The application should demonstrate that the research team's background is appropriate to successfully achieving the proposed research and contributing to the field of PD research. The PRP IIRA requires that the PI dedicate at least 15% of their full-time professional effort to this award during the award period.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.